HengRui USA Announces First US Patient Screened in Study Evaluating INS068 in Patients with Type 2 Diabetes Mellitus
Feb 05, 2021
Company Announcement
HengRui USA announced today that the screening of patients with type 2 diabetes mellitus in a study comparing INS068 with Tresiba® (insulin degludec) has started.
The study evaluates the efficacy and safety of INS068 and Insulin Degludec subcutaneous injection once daily in subjects with Type 2 diabetes mellitus not adequately controlled with one or two oral antidiabetics and is a phase 2, randomized, open-label, two-arm, treat-to-target, parallel controlled trial (NCT04663282).
About INS068
INS068 injection is a long-acting human insulin analog injection, and is currently being developed for the treatment of both type 1 and type 2 diabetes mellitus.
HengRui USA announced today that the screening of patients with type 2 diabetes mellitus in a study comparing INS068 with Tresiba® (insulin degludec) has started.
The study evaluates the efficacy and safety of INS068 and Insulin Degludec subcutaneous injection once daily in subjects with Type 2 diabetes mellitus not adequately controlled with one or two oral antidiabetics and is a phase 2, randomized, open-label, two-arm, treat-to-target, parallel controlled trial (NCT04663282).
About INS068
INS068 injection is a long-acting human insulin analog injection, and is currently being developed for the treatment of both type 1 and type 2 diabetes mellitus.